Rifampin adverse event reports that FDA received

Name: Reaction terms in FDA adverse event reports that name Rifampin
Creator: Reported Reactions
License: https://creativecommons.org/publicdomain/zero/1.0/

Name type: Generic name
Class: Rifamycin antibacterial
Also reported as: Rifampin Capsules Usp, Rifampin Capsule, Rifampin 300mg

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 9,224 adverse event reports that name Rifampin. In these reports the drug is a suspect or interacting product.

In the same period, 5,473 further reports name it only as a concomitant medicine. The counts on this page do not include these reports.

FDA received 1,367 reports in the 12 months to June 2026 and 1,371 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate. A count of reports is not a count of events or of patients, because one event can have more than one report.

There are many instances of duplicative reports and some reports do not contain all the necessary information.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Suspect product

FDA records each drug in a report as suspect, concomitant or interacting. This page counts the reports in which Rifampin is suspect or interacting. FDA says:

Any number of the drugs may be marked as suspect if thought to be responsible for one or more of the reactions, but that information is not validated.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Since the last update

FDA says:

Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The information in these reports cannot be used to estimate the incidence (occurrence rates) of the events reported.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

No update is on record for this page. The record starts when FDA adds the reports of July to September 2026.

In April to June 2026, FDA received 262 reports that name Rifampin.
In January to March 2026, FDA received 381.
In April to June 2025, FDA received 265.

April to June 2026 is the latest closed quarter in the data. A closed quarter is a quarter for which the FDA files have most of the reports.

All updates Feed of updates (RSS)

Reaction lookup

These are the reaction terms that the reports record, with the number of reports for each term. Type a term or a plain word to find its count.

What this list leaves out

The table lists the 698 reaction terms that 5 or more reports record. A term with fewer than 5 reports is not in the table.

The site keeps reaction terms for 9,201 of the 9,224 reports (99.8%).

The reports of the other years are not in the counts.

So a count in the table can be lower than the count of FDA.

Find a reaction term

The table shows the first 50 of 698 terms.

Reaction terms in the reports that name Rifampin, most reports first
Reaction term (MedDRA) and plain meaning	Reports	Share of the 9,224 reports
Drug ineffectivethe medicine did not work as expected	1,117	12.1%
Drug interactionan interaction between medicines	978	10.6%
Off label useused for a purpose or in a way not on the label	612	6.6%
Drug reaction with eosinophilia and systemic symptomsDRESS, a severe reaction with rash, fever and organ involvement	598	6.5%
Product use in unapproved indicationused for a purpose not on the label	487	5.3%
Condition aggravatedthe condition being treated got worse	447	4.8%
Nauseafeeling sick	396	4.3%
Drug resistance	393	4.3%
Paradoxical drug reaction	378	4.1%
Pyrexiafever	349	3.8%
Drug intolerancethe medicine was not tolerated	345	3.7%
Vomitingbeing sick	318	3.4%
Drug-induced liver injury	305	3.3%
Rashskin rash	290	3.1%
Acute kidney injurysudden loss of kidney function	284	3.1%
Treatment failurethe treatment did not work	281	3%
Drug ineffective for unapproved indication	229	2.5%
Thrombocytopenialow platelets	224	2.4%
Diarrhoealoose or frequent stools	205	2.2%
Pruritusitching	182	2%
Mycobacterium avium complex infection	175	1.9%
Fatiguetiredness	173	1.9%
Eosinophilia	165	1.8%
Neutropenialow neutrophils, a type of white blood cell	164	1.8%
Cough	162	1.8%
Hepatic cytolysis	162	1.8%
Dyspnoeashortness of breath	161	1.7%
Tuberculosis	159	1.7%
Hepatotoxicityliver injury	158	1.7%
Drug hypersensitivityan allergic-type reaction (the term names a medicine)	146	1.6%
Immune reconstitution inflammatory syndrome	146	1.6%
Rash maculo-papulara rash of flat and raised spots	146	1.6%
Toxicity to various agentspoisoning or toxic effect of one or more substances	140	1.5%
Headachehead pain	129	1.4%
Tubulointerstitial nephritis	124	1.3%
Decreased appetitereduced appetite	123	1.3%
Anaemialow red blood cells	119	1.3%
Weight decreasedweight loss	117	1.3%
Abdominal painstomach or belly pain	115	1.2%
Acute hepatic failure	115	1.2%
Gastrointestinal disorder	111	1.2%
Arthralgiajoint pain	109	1.2%
Disease progressionthe disease advanced	104	1.1%
Astheniaweakness or lack of energy	102	1.1%
Drug level decreaseda low blood level of the medicine	101	1.1%
Multiple organ dysfunction syndromeseveral organs failing	95	1%
Therapy non-responderthe treatment did not work	95	1%
Painpain, site not specified	93	1%
Disseminated tuberculosis	91	1%
Hepatitis	88	1%

Download all 698 terms of Rifampin (CSV)

The counts add to more than 9,224 reports, because one report can record more than one term. FDA says:

No individual drug is connected to any individual reaction. When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The CSV file has the same rows and the same limits. Its last row is a note that says so.

MedDRA term

The person who codes a report selects the preferred term that agrees best with the description of the reporter. The words under a term are the plain meaning that this site gives.

Not the label

The FDA-approved label of a product lists its adverse reactions. See the official pages at the end of this page.

Outcomes by year

The table gives the outcomes that the reporters gave, in the terms of FDA.

Outcomes in the reports that name Rifampin, by the year of the openFDA file that holds the report

The table continues to the right.

Year of the openFDA file	Reports	Serious	Death	Life-threatening	Hospitalization (initial or prolonged)	Disability or Permanent Damage	Congenital Anomaly/Birth Defect	Other Serious (Important Medical Events)	Not serious
2004	20	18	2	0	13	1	0	9	2
2005	34	32	4	4	18	2	0	12	2
2006	33	30	12	1	13	0	0	6	3
2007	26	25	0	5	15	1	0	11	1
2008	32	27	4	4	18	1	0	9	5
2009	37	34	4	5	20	2	0	9	3
2010	62	56	12	5	32	5	0	19	6
2011	109	100	19	9	69	3	0	47	9
2012	72	57	8	1	24	0	0	35	15
2013	131	126	16	9	60	6	0	96	5
2014	97	86	14	8	44	2	1	46	11
2015	206	177	17	12	51	2	6	125	29
2016	187	161	20	2	72	3	0	104	26
2017	305	264	38	21	114	4	2	178	41
2018	299	259	23	20	91	4	3	200	40
2019	385	333	37	17	122	3	1	287	52
2020	304	250	28	18	105	5	0	194	54
2021	725	639	47	28	302	17	3	489	86
2022	1,227	1,114	115	88	635	15	5	747	113
2023	1,371	1,044	116	67	496	17	5	818	327
2024	1,380	1,198	111	83	559	8	0	945	182
2025	1,445	1,165	123	89	558	13	6	907	280
2026	737	629	87	69	349	10	1	448	108

An outcome in a report is not proof that the drug was the cause. The reporter gives the outcome, and FDA does not verify it. FDA says:

The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The six headings with the names of FDA are the outcome terms of FDA. A report can have more than one outcome. The columns Serious and Not serious are the two values of the openFDA field serious. For the value serious, openFDA gives this description:

The adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition
Source: openFDA, Drug adverse event fields (YAML reference). The site read the page on 2 Oct 2026.

The year is the year of the openFDA file that holds the latest version of the report. It is not always the year in which FDA first received the report. The chart of the next section uses the year of first receipt. The latest year is not complete.

Reports by year and month

Reports that name Rifampin, by the year in which FDA received them

The column of 2026 has an outline, because the year is not complete. It has the reports that FDA received through June 2026 only.

Show the figures of the chart as a table

Reports that name Rifampin, by the year in which FDA received them
Year	Reports
2004	18
2005	36
2006	33
2007	27
2008	34
2009	37
2010	63
2011	109
2012	84
2013	130
2014	111
2015	210
2016	221
2017	320
2018	367
2019	448
2020	378
2021	788
2022	1,139
2023	1,311
2024	1,375
2025	1,342
2026	643

Reports that name Rifampin, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Why a count moves

A count moves for many reasons. The guide gives FDA's words about them.

Patients and reporters

Age of the patient in the reports that name Rifampin
Age	Reports	Share
Under 2	135	1.5%
2 to 11	246	2.7%
12 to 17	304	3.3%
18 to 44	2,127	23.1%
45 to 64	1,848	20%
65 to 74	1,291	14%
75 and over	1,166	12.6%
Age not given	2,107	22.8%

Sex of the patient in the reports that name Rifampin
Sex	Reports	Share
Female	4,065	44.1%
Male	4,203	45.6%
Unknown or not given	956	10.4%

Type of reporter in the reports that name Rifampin
Reporter	Reports	Share
Physician	3,396	36.8%
Pharmacist	756	8.2%
Other health professional	4,145	44.9%
Lawyer	4	under 0.1%
Consumer or non-health professional	780	8.5%
Not given	143	1.6%

Age and sex are as the report gives them. The reporter is the primary source in the report. 37.2% of the reports give the United States as the country.

Reason for use

Reason for use (indication) that the reports of Rifampin record
Indication as recorded (MedDRA)	Reports	Share
Tuberculosis	1,400	15.2%
Mycobacterium avium complex infection	871	9.4%
Pulmonary tuberculosis	698	7.6%
Disseminated tuberculosis	268	2.9%
Staphylococcal infection	181	2%
Device related infection	150	1.6%

The reporter fills in the indication, and the field is often empty. Each share is of all 9,224 reports.

Drugs in the same reports

Other drugs that the reports of Rifampin name, in any role, in order of name
Drug	Reports that name the two
Amikacin	738
Azithromycin	1,279
Clarithromycin	558
Ethambutol	3,258
Isoniazid	3,053
Levofloxacin	1,122
Linezolid	663
Moxifloxacin	694
Pyrazinamide	2,502
Vancomycin	601

The table has the 10 drug names that these reports name most. Two names in one report says only that the report recorded the two. It says nothing about the part of a product in the event.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pages near this one

Rifaximin same class
Xifaxan same class
Rifampicine next in the A to Z list
Rifapentine next in the A to Z list
Rifampicin next in the A to Z list
Rifater next in the A to Z list
Rifadine next in the A to Z list
Rifadin next in the A to Z list
Rifinah next in the A to Z list
Rifabutin next in the A to Z list
Rilmenidine next in the A to Z list
Ribomustin next in the A to Z list

These links are for navigation. No count selected them. The class page lists each drug of the class.

Official pages

DailyMed labels for RifampinThe labels (prescribing information) that have this name, at the National Library of Medicine.
MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Rifampin: adverse event reports that FDA received. https://reportedreactions.com/drug/rifampin/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 1 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

A report is in the count when it names Rifampin as a suspect or interacting product. The 5,473 reports that name it only as a concomitant medicine are not in the count. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

Do these reports show that Rifampin was responsible for the reactions?

No. FDA says:

For any given report, there is no certainty that a suspected drug caused the event.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

A reaction can relate to the condition that the drug treats, to other medicines, or to something else.

Is this the list of reactions on the label of Rifampin?

No. It is a count of what people reported to FDA: 9,224 reports from January 2004 to June 2026. The FDA-approved label of a product lists its adverse reactions. The official pages at the end of this page link to the labels.

Who sent these reports?

Other health professional (44.9%), physician (36.8%) and consumer or non-health professional (8.5%). These are the types of reporter for the reports that name this drug.

If a manufacturer receives an adverse event report, it is normally required to send the report to FDA.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

How does a person report an adverse event?

FDA runs MedWatch, a program that takes voluntary reports from health professionals, patients and consumers. The guide on how to report has the links.

To the top of the page